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RESUMO.- [Fator Estimulante de Colônias de Granu-
lócitos e Macrófagos (GM-CSF) não aumenta a eficácia
ou potência da vacina de subunidades da Febre Aftosa
em suínos.] A febre aftosa é uma das doenças mais temidas nos
rebanhos em todo o mundo. A vacinação tem sido uma arma
eficiente no controle da doença, no entanto há preocupações
com as vacinas atualmente utilizadas incluindo a necessidade de
instalações de alta segurança para a produção dessas vacinas e
a falta de um teste de diagnóstico aprovado que faça distinção
precisa entre animais vacinados dos infectados. Várias vacinas
têm sido testadas contra a febre aftosa e uma dessas utiliza como
vetor um vírus defectivo para replicação, derivado do adenovírus
humano tipo 5 (Ad5), o qual contém as proteínas que compõe
capsídeo do vírus da febre aftosa (P1-2A) e a protease 3C, prote-
geu completamente suínos contra o desafio de uma cepa
homóloga (A12 e A24). Uma vacina com o Ad5-P1-2A+3C prove-
niente da cepa O1 Campos (Ad5-O1C), no entanto, somente in-
duziu um baixo título de anticorpos neutralizantes específicos
em testes de potência vacinal em suínos.  O fator estimulante de
colônias de granulócitos e macrófagos (GM-CSF) tem sido utiliza-
do com sucesso na formulação de vacinas para estimular a res-
posta imune contra inúmeras doenças, incluindo HIV, Hepatite C
e B. Na tentativa de melhorar a resposta imune específica contra
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Foot-and-mouth disease (FMD) is one of the most feared diseases of livestock worldwide.
Vaccination has been a very effective weapon in controlling the disease, however a number of
concerns with the current vaccine including the inability of approved diagnostic tests to reliably
distinguish vaccinated from infected animals and the need for high containment facilities for
vaccine production, have limited its use during outbreaks in countries previously free of the
disease. A number of FMD vaccine candidates have been tested and a replication-defective human
adenovirus type 5 (Ad5) vector containing the FMDV capsid (P1-2A) and 3C protease coding regions
has been shown to completely protect pigs against challenge with the homologous virus (FMDV
A12 and A24). An Ad5-P1-2A+3C vaccine for FMDV O1 Campos (Ad5-O1C), however, only induced
a low FMDV-specific neutralizing antibody response in swine potency tests. Granulocyte-macrophage
colony-stimulating factor (GM-CSF) has been successfully used to stimulate the immune response in
vaccine formulations against a number of diseases, including HIV, hepatitis C and B. To attempt to
improve the FMDV-specific immune response induced by Ad5-O1C, we inoculated swine with Ad5-
O1C and an Ad5 vector containing the gene for porcine GM-CSF (pGM-CSF). However, in the
conditions used in this trial, pGM-CSF did not improve the immune response to Ad5-O1C and
adversely affected the level of protection of swine challenged with homologous FMDV.
INDEX TERMS: Foot-and-mouth disease virus O1 Campos, Adenovirus, Granulocyte-macrophage colony-
stimulating factor.
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a febre aftosa induzida pelo Ad5-O1C, suínos foram vacinados
com Ad5-O1C juntamente com Ad5-GM-CSFporcino. Entretanto
nas, condições utilizadas nesse teste, o GM-CSF suíno não melho-
rou a resposta imune do Ad5-O1C e adversamente afetou o nível
de proteção de suínos desafiados com o vírus homólogo da
febre aftosa.
TERMOS DE INDEXAÇÃO: Febre Aftosa Vírus O1 Campos, Adenovirus,
Fator Estimulante de Colônias de Granulócitos e Macrófagos.
INTRODUCTION
Foot-and-mouth disease (FMD) is a highly contagious, acute
disease of domestic and wild cloven-hoofed animals (Callis &
McKercher 1986, Donaldson et al. 1986). The etiologic agent,
FMD virus (FMDV), is a member of the Aphthovirus genus
Picornaviridae family (Murphy et al. 1999) and contains a single-
stranded, positive-sense RNA genome of approximately 8.5kb.
The virus consists of seven serotypes (O, A, C, SAT 1-3 and Asia)
and multiple subtypes within each serotype.
FMD outbreaks can result in significant economic losses in
disease-free countries due to direct and indirect costs, most of
which are related to international trade embargoes of animals
and animal products. Recent outbreaks in Taiwan and the United
Kingdom have highlighted the major risk of introduction and
rapid spread of FMD in a susceptible population (Mathews 2001).
Currently, conventional binary ethyleinimine (BEI) inactivated
vaccines emulsified with adjuvant have been widely used in
effective control and eradication programs around the world
(Brownlie 2001). However, there are no approved diagnostic
tests that can reproducibly differentiate vaccinated from infected/
convalescent animals. Furthermore, conventional vaccines
require growth and inactivation of live virus in containment
facilities and introduce the potential for escape of live virus or
incomplete inactivation (Barteling & Vreeswijk 1991). As a result
some FMD-free countries have not considered vaccination as
part of their disease control strategy.
Several approaches are being used to develop alternative
FMD vaccines that address these concerns, including
construction of modified live-virus (Mason et al. 1997, Almeida
et al. 1998), biosynthetic proteins (Kleid et al. 1981, McKercher
et al. 1985), synthetic peptides (Bittle et al. 1982, Clark et al.
1983, Brown 1988, Blanco et al. 2001), naked DNA vectors (Ward
et al. 1997, Chinsangaram et al. 1998, Wong et al. 2000,
Benvenisti et al. 2001, Cedillo-Barrón et al. 2001), and
recombinant viruses (Sanz-Parra et al. 1999a,b, Mayr et al. 1999,
2001, Berinstein et al. 2000, Moraes et al. 2002, Wu et al. 2003b).
However, most of these approaches have either been
unsuccessful in both swine and cattle or require multiple
inoculations to induce protection.
Human adenovirus (Ad5) has been used as a vector for FMD
vaccines encoding the capsid (P1-2A) (Sanz-Parra et al. 1999a,b)
or P1-2A and 3C protease coding regions of FMDV (Mayr et al.
1999, 2001, Moraes et al. 2002, Wu et al. 2003b). Inoculation
with one dose of Ad5 containing the serotypes A24 Cruzeiro P1-
2A and A12 3C coding regions (Ad5-A24) protected swine from
direct inoculation challenge with homologous virus (Moraes et
al. 2002).  More recently we have attempted to develop Ad5
vaccine vectors for other FMDV serotypes, in particular isolates
of serotype O that are currently causing disease outbreaks
throughout the world. We have constructed Ad5 and Ad2 vectors
containing the P1-2A region of O1 Campos and the 3C of A12
(Ad5-O1C) and found that swine inoculated with these vectors
developed a lower FMDV-specific neutralizing antibody response
than Ad5-A24 inoculated animals (unpublished data). Likewise,
swine inoculated with an Ad5-FMD bivalent vaccine containing
the P1-2A regions from A24 Cruzeiro and O1C developed a higher
neutralizing antibody response against A24 than against O1 (Wu
et al., 2003b). It has been established that serotype O antigen
induces a lower immune response as compared to serotype A
antigen (Pay & Hingley 1987, Doel et al. 1994). Because of this
commercial vaccines usually contain about 4-5 times more O1
inactivated virus (146S antigen) than A 146S antigen.
The use of cytokines to modulate responses against
immunization with DNA and recombinant virus vectors is being
actively investigated. Granulocyte-macrophage colony-
stimulating factor (GM-CSF), a hematopoietic growth factor, has
been widely used as a molecular adjuvant to induce immunity.
GM-CSF activates neutrophils, macrophages, dendritic cells (DCs),
and other mononuclear cells, and also stimulates progenitor/
stem cells to mature and migrate from the bone marrow to the
peripheral circulation (Kusakabe et al. 2000). Intramuscular (IM)
inoculation of the GM-CSF gene together with plasmids carrying
viral genes, such as those encoding the glycoprotein of rabies
virus and VP1 of encephalomyocarditis virus, increased antigen-
specific immune responses and protective immunity in mice as
compared to inoculation with the plasmid containing only the
viral gene (Xiang & Ertl 1995, Sin et al. 1997). Somasundaram et
al. (1999) found an adjuvant effect of porcine GM-CSF (pGM-CSF)
on a DNA vaccine containing the gD and gB glycoprotein genes
of Aujeszky’s disease virus (PRV) in pigs. This effect was
characterized by an early appearance of anti-PRV IgG2, a
significantly enhanced anti-PRV IgG1 and IgG2 antibody
response, a significantly decreased and shortened period of virus
shedding in nasal swabs and improved protection against viral
challenge. In contrast, co-administration of porcine IFN- or IL-2
had no adjuvant effect.
Lee et al. (1998), observed that both humoral and cellular
immune responses to hepatitis C virus (HCV) envelope proteins
were augmented in rats by the co-delivery of the GM-CSF gene.
Moreover, inoculation of bicistronic plasmids elicited higher
levels of antibody and lymphoproliferative responses than did
the co-inoculation of two independent expression plasmids that
encoded the GM-CSF gene and each HCV envelope gene. Similarly
Barouch et al. (2002) demonstrated that a bicistronic plasmid
containing GM-CSF and HIV gp120 elicited a dramatic
augmentation of vaccine-elicited CD4+ T cell responses in mice
as compared to gp120 alone or individual plasmids containing
each gene. These results suggest that the local concentration of
GM-CSF may be a critical factor that contributes to the
enhancement of the immune response to the co-expressed
antigens. It has also been demonstrated that the time of
administration of GM-CSF with respect to the DNA antigen vaccine
can profoundly influence the nature of the Th1/Th2 balance of
an antigen-specific immune response (Kusakabe et al. 2000).
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We have tested pGM-CSF as an adjuvant for our Ad5-O1C
vaccine and have delivered this cytokine with a recombinant
Ad5 vector. We have previously utilized the Ad5 vector system to
effectively deliver various cytokines including type I interferons
(IFN-/) to swine (Chinsangaram et al. 2003, Moraes et al. 2003;
Wu et al., 2003a) and cattle (Wu et al., 2003a). Swine inoculated
with both Ad5-pGMCSF and Ad5-O1C, however, did not develop
an enhanced immune response against O1C as compared to
Ad5-O1C inoculated animals and administration of pGM-CSF had




All adenovirus clones were generated, grown, and titered in
human 293 cells (Graham et al. 1977, Graham & Prevec 1991),
between passages 20 and 30. Plaque reduction neutralization
assays with FMDV were performed in baby hamster kidney 21
cells (BHK-21) between passages 62 and 70. TF-1 cells, obtained
from the American Type Culture Collection, are an indicator cell
clone that is dependent on human GM-CSF or IL-3 for growth.
These cells were used to analyze the biological activity of pGM-
CSF obtained from the supernatants of IB-RS-2 cells (Instituto
Biológico-Rim Suíno 2) infected with Ad5-pGMCSF, as pGM-CSF
supports growth of this cell line as well.
Construct ion of  recombinant adenoviruses Ad5-
pGMCSF and Ad5-O1C
The pGM-CSF gene, containing the signal sequence, was
obtained from plasmid p3CIa-pGM-CSF kindly provided by Dr.
Steve Martin, Pharmacia-UpJohn. This plasmid was digested with
HindIII and EcoRI, ligated to similarly digested pBluescript II KS
(Stratagene, La Jolla, CA) and chemically transformed into Top
10 competent cells (Invitrogen, Carlsbad, CA) to generate the
plasmid, pKSII-pGMCSF. The coding sequence of pGM-CSF was
removed from pKSII-pGMCSF by digestion with ClaI and XbaI
and ligated into similarly digested pAd5-Blue (Moraes et al. 2001)
to generate the infectious clone pAd5-pGMCSF. Recombinant virus
Ad5-pGMCSF was produced by transfection of 293 cells with
PacI digested pAd5-pGMCSF following the protocol described
(Wu et al., 2003b). The virus was isolated, propagated in 293
cells, and purified by CsCl gradient centrifugation (Mayr et al.,
1999; Moraes et al., 2002).
To construct Ad5-O1C, the infectious clone pCRM8 (Sá-Car-
valho et al., 1997) a chimeric FMDV clone containing the P1-2A
coding region of FMDV O1C in the background of FMDV A12,
was digested with NcoI, ApaI to remove the O1C P1-2A coding
region. Plasmid pP12X3C (Mayr et al., 1999), which contains the
complete P1-2A and 3C coding regions and partial 2B and 3B
coding regions of FMDV A12, was digested with the same enzymes
to remove the A12 P1-2A coding region and ligated to O1C P1-
2A to generate pP1-2A(O1C)X3C. This plasmid was digested with
BglII and XbaI to remove the O1C P1-2A and A12 3C coding
regions and ligated to similarly digested Ad5 transfer vector
pShuttle (He et al., 1998). pShuttle-P1-2A(O1C)X3C was digested
with ClaI and XbaI and the fragment containing the FMDV coding
regions was ligated to similarly digested pAd5-Blue to generate
pAd5-O1C. Recombinant virus Ad5-O1C was produced by
transfection of 293 with PacI digested pAd5-O1C and purified
virus prepared as described above. In both the Ad5-pGMCSF and
Ad5-01C viruses the inserted coding regions are under the control
of the cytomegalovirus (CMV) immediate early promoter (Moraes
et al., 2001).
Expression of pGM-CSF and O1C capsid proteins
synthesized in Ad5-pGMCSF or Ad5-O1C infected cells
IB-RS-2 cells were grown in 6 well plates and infected with
Ad5-pGMCSF or Ad5-O1C at a multiplicity of infection (moi) of 20.
At 5 or 23 h postinfection (hpi), the cells were preincubated for 1
h in methionine-free culture medium in the absence or presence
of 5 g/ml tunicamycin, followed by radiolabeling for 1 h with
[35S]methionine in methionine-free medium in the absence or
presence of tunicamycin. The supernatants were harvested, frozen
at -70oC and the cells were washed twice with PBS, lysed,
centrifuged and the cytoplasmic extracts frozen at -70oC. Samples
were immunoprecipitated with polyclonal goat anti-pGM-CSF
antibody (R&D Systems, Minneapolis, MN) or various FMDV-specific
antisera as described in the captions to Figs. 1 and 3 and the
immune complexes were precipitated with Streptococcus aureus
protein G (Calbiochem, San Diego, CA) and analyzed by SDS-
polyacrylamide gel electrophoresis (SDS-PAGE) on a 15% gel. The
gels were dried and exposed to Kodak XDBF-1® X-ray film.
Alternatively IB-RS-2 cells were infected at a moi of 20 with
Ad5-pGMCSF for 24 h. Supernatant fluids were harvested and
centrifuged at 2000 rpm for 10 min. To remove the majority of
virus inoculum, the supernatants fluids were filtered through a
Centricon 100 filter (Millipore, Bedford, MA) and frozen in aliquots
at -700C. Aliquots were examined for pGM-CSF expression by
Western blot analysis on a 10% precast polyacrylamide gel, (NuPAGE,
Invitrogen) and transferred to a PVDF membrane (Millipore). Protein
was detected using a polyclonal goat anti-pGM-CSF antibody (R&D
Systems), phosphatase labeled rabbit anti-goat polyclonal antibody,
and BCIP/NBT phosphatase substrate following the manufacturer’s
instructions (KPL, Gaithersburg, MD).
Biological activity of pGM-CSF synthesized in Ad5-
pGMCSF infected cells
Biological activity was measured using a Cell Proliferation
ELISA System RPN 250 (BIOTRAK® Amersham Pharmacia Biotech,
Piscataway, NJ). A standard curve was generated by growth of
TF-1 cells, in 96-well tissue culture plates, in the presence of
dilutions of recombinant pGM-CSF (R&D Systems) (Kitamura et
al., 1989). Dilutions of supernatant fluids from Ad5-pGMCSF
infected IB-RS-2 cells were added, in duplicate, to a 96-well plate
containing TF-1 cells. After 5 days incubation, bromodeoxyuridine
(BrdU) was added and cells labeled for approximately 20 h. Cell
proliferation was measured following the manufacturers
recommended protocol (Bautista et al. 2002).
Animals
Eighteen out-bred Yorkshire gilts approximately 7-8 weeks
old, weighting between 35-40 lbs, were divided into five groups
and each group was housed in a separate room in the high-
containment facilities at the PIADC. All animals were handled
humanely according to protocols approved by the Animal Care
and Use Committee (ACUC) of PIADC. The animals were observed
for one week prior to the start of the experiment. The vaccine
was administrated by IM inoculation in the neck with 2 ml of
various doses of Ad5 vectors in PBS (Table 1). All animals were
challenged 21 days post vaccination (dpv) and 35 dpv the
remaining pigs were humanely euthanised.
Serology and virus isolation
Serum samples were obtained at 0 and 4 days after
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inoculation and weekly thereafter. Sera were tested for the
presence of neutralizing antibodies against FMDV O1C, in a
plaque reduction neutralization (PRN) assay. Neutralization titers
were reported as the serum dilution yielding a 70% reduction in
the number of plaques (PRN70) (Moraes et al. 2002).
Heparinized blood was obtained prior to challenge and daily
for 7 days postchallenge (dpc) and examined for the presence of
virus by a standard plaque assay in BHK-21 cells. Nasal secretions
were obtained on the same days as heparinized blood, inoculated
into IB-RS-2 cells, and observed for 48 h for cytopathic effects.
Negative samples were frozen and a second passage performed.
For positive samples, titration was performed from the original
samples by a plaque assay on BHK-21 cells.
Challenge
The 18 animals were challenged with homologous FMDV
O1C 21 days after receiving the respective vaccine combinations
(Table 1). FMDV O1C was provided by the Instituto Pan-America-
no de Febre Aftosa, Rio de Janeiro (PANAFTOSA). This virus was
passed 5 times in BHK-21 cells, and once each in a bovine and a
pig. Virus was harvested from vesicles of an infected pig, diluted
with MEM, centrifuged at 2000g to remove debris, aliquoted,
and frozen at -70ºC. An aliquot was titrated in BHK-21 cells and in
4 pigs to determine the “pig heel infectious dose 50%” (PHID50)
as previously described (Burrows 1966). Pigs were infected with
100 PHID50 by intradermal inoculation at 2 sites in the heel bulb
of the rear feet.
RESULTS
Ad5-pGMCSF and Ad5-O1C expression
IB-RS-2 cells were infected with Ad5-pGMCSF and at 6 or 24
hpi were radiolabeled with [35S]methionine in the absence or
presence of 5 g/ml tunicamycin. The cell culture supernatants
were examined by SDS-PAGE. As can be seen in Fig. 1 (lane 2)
multiple bands are present in the supernatant at 24 hpi, while in
the supernatant from cells treated with tunicamycin a single band
is present (lane 3). This band is immunoprecipitated by polyclonal
serum that was produced against E. coli-expressed pGM-CSF (lane
6). These results are in agreement with published sequence data
indicating that mature pGM-CSF has three potential N-linked
glycosylation sites (Inumaru & Takamatsu 1995). The inefficient
immunoprecipitation of glycosylated pGM-CSF (lane 5) may be the
result of interference with the antigen-antibody reaction by the
extensive glycosylation of this protein. We further analyzed
production of pGM-CSF in IB-RS-2 cells by Western blot analysis
and show glycosylated pGM-CSF is efficiently detected, suggesting
that denatured protein is a better antigen for this polyclonal
antibody (compare Fig. 2, lanes 6 and 7 to Fig. 1, lane 5).
To examine the expression of O1C capsid proteins by Ad5-
O1C, IB-RS-2 infected cells were radiolabeled, cell lysates prepared
at 5-7 hpi, immunoprecipitated with various FMDV-specific
antibodies, and analyzed by SDS-PAGE (Fig. 3). We and others
have previously shown that the A12 3C protease can efficiently
process the P1-2A precursor from A24, O1C, and O1 Taiwan/99
(Sa-Carvalho et al. 1997, Almeida et al. 1998, Moraes et al. 2002,
Wu et al. 2003b unpublished). Reaction with bovine convalescent
serum precipitated the structural proteins VP0, VP3, and VP1
(lanes 2 and 4). Likewise monospecific polyclonal antibodies
against FMDV A12 VP1 and VP2, which we have previously
demonstrated immunoprecipitates O1C structural proteins
(Grubman et al. 1987), each precipitates all 3 O1C structural
proteins (lanes 5 and 6) suggesting that FMDV capsid protein
complexes are assembled in Ad5-O1C infected cells. We have
previously observed similar results in cells infected with other
Table 1. Serum neutralization titers after vaccination and clinical scores
Animal Group Virus constructs Dose (PFU/animal) Clinical Weeks post-vaccination (PRN70)
a
scoresb 0 ½c 1 2 3 (Challenge)  4 5
2107 1 Ad5-Blue 1X109 16 <8 <8 <8 <8 <8 Dead
2108 1 18 <8 <8 <8 <8 <8 Dead
2109 1 18 <8 <8 <8 <8 <8 Dead
2110 2 Ad5-pGMCSF 1X109 17 <8 <8 <8 <8 <8 160 1000
2111 2 15 <8 <8 <8 <8 <8 Dead
2112 2 17 <8 <8 <8 <8 <8 640 1000
2104 3 Ad5-O1C 5X109 11 <8 <8 16 16 <16 2560 2000
2113 3  8 <8 <8 <8 8 <16 4000 1000
2114 3 11 <8 <8 32 64 32 4000 2000
2115 3 8 <8 <8 8 16 16 2560 2000
2105 4 Ad5-O1C+ Ad5-pGMCSF 5X109+1X108 9 <8 16 16 32 16 8000 2000
2116 4 12 <8 8 16 16 <16 4000 2000
2117 4 10 <8 16 64 16 <16 8000 8000
2118 4 15 <8 8 16 16 <16 2560 4000
2106 5 Ad5-O1C + Ad5-pGMCSF 5X109+1X109 12 <8 8 32 32 16 4000 4000
2119 5 11 <8 32 64 32 16 4000 4000
2120 5 9 <8 8 32 16 <16 1240 4000
2121 5 13 <8 8 16 16 <16 4000 2000
a Serum dilution that reduces the number of plaques by 70%; b Clinical scores were determined by the number of toes presenting FMD
compatible lesions plus the presence of lesions in the snout and mouth, with a maximum score of 18; we did not count a lesion
found at the site of inoculation; the score listed was determined at 9 dpc or the day of death; c Four days post-vaccination.
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Ad5-FMDV viruses (Mayr et al. 1999, Moraes et al. 2002, Wu et al.
2003b).
The biological activity of pGM-CSF obtained from supernatant
fluids of Ad5-pGMCSF infected IB-RS-2 was measured in vitro by
a TF-1 cell proliferation assay. As shown in Fig. 4, Ad5 expressed
pGM-CSF has biological activity as demonstrated by the support
of TF-1 cell growth, while supernatant fouids from a control Ad5
lacking the pGM-CSF gene, Ad5-Blue, had no biological activity.
Immune response prior to challenge
To examine the potency and efficacy of Ad5-O1C in
susceptible animals and determine if pGM-CSF can enhance the
immune response of the FMDV antigens, 3 groups of swine, 4
animals per group, were inoculated IM with Ad5-O1C at 5x109
pfu/ml in the absence (Group 3) or presence of 1x108 or 1x109
pfu/animal Ad5-pGMCSF (Groups 4 and 5, Table 1). Control
groups, 3 animals per group, were inoculated with an Ad5 vector,
Ad5-Blue (Group 1), or with Ad5-pGMCSF alone (Group 2).
After vaccination no adverse side effects, such as fever, apathy
or inflammation at the inoculation site, were observed in any of
the pigs. The FMDV-specific neutralizing antibody titers of the
Ad5-O1C inoculated animals were detectable by 4-7 dpi, but were
low and were not increased by co-administration of Ad5-pGMCSF
(Table 1, Fig. 5). As expected the animals in the control groups
did not develop an FMDV-specific neutralizing antibody titer.
Clinical response after challenge
All animals were challenged 21 dpv. After challenge, swine in
the control groups (1 and 2) developed a fever (temperature of
40°C or higher for 2 or more consecutive days) by 1-2 dpc and
vesicular lesions by 1 dpc. All of these animals had extensive
disease by 2-3 dpc (Fig. 6). Between 3-5 dpc all animals in control
group 1, that received the Ad5-Blue vector, died and on day 3
one animal in group 2, that received Ad5-pGMCSF, also died.
Upon necropsy, these four animals all had extensive signs of
heart necrosis (tiger heart) which was confirmed by histo-
pathological examination. These cardiac complications are typical
causes of death as a result of FMDV infection in young swine.
The two control animals that survived each lost at least one hoof
by one week postchallenge.
Nine of twelve of the vaccinated pigs (Groups 3, 4 and 5)
developed fever by 2-5 dpc, while 1 pig in group 3 and two in
group 4 never had fever. All vaccinated swine developed signs of
infection, but the onset of disease was delayed 1-2 days compared
to the controls, disease severity was reduced, and no animals in
these groups died or lost their hoofs (Fig. 6). The group that
received only Ad5-O1C (Group 3) had a slightly reduced clinical
Fig.1. Expression of pGM-CSF in Ad5-pGMCSF infected IB-RS-2 cells.
IB-RS-2 cells were infected with Ad5-pGMCSF and radiolabeled
with [35S]methionine in the absence or presence of tunicamycin.
Supernatant fluids were harvested and proteins were resolved by
SDS-PAGE on a 15% gel or immunoprecipitated with a polyclonal
antibody against pGM-CSF and subsequently resolved by SDS-
PAGE. Lane 1: Supernatant fluid from cells infected for 6 h and
radiolabeled in the absence of tunicamycin. Lanes 2-3: Supernatant
fluids from cells infected for 24 h and radiolabeled in the absence
or presence of tunicamycin, respectively. Lane 4: Immuno-
precipitation of supernatant fluids from mock-infected,
radiolabeled cells. Lanes 5-6: Immunoprecipitation of supernatant
fluids from cells infected for 24 h and radiolabeled in the absence
or presence of tunicamycin, respectively.
Fig.2. Western blot analysis of supernatant fluids from Ad5-pGMCSF
infected IB-RS-2 cells. Samples were resolved on a precast 10%
polyacrylamide gel, transferred to a membrane and detected with
a polyclonal goat anti-pGM-CSF antibody. Lanes 1-5: 0.5, 1, 5, 10,
and 20 ng of recombinant pGM-CSF. Lanes 6-7: 2 and 9.8 l
supernatant fluids from Ad5-pGMCSF infected IB-RS-2 cells. Lane
8: 9.8 l supernatant fluid from mock-infected IB-RS-2 cells. Lane
9: molecular weight marker. The numbers on the right represent
molecular mass in kilodaltons.
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score as compared to the groups that received both Ad5-O1C
and Ad5-pGMCSF (Groups 4 and 5).
Serological response after challenge
The two surviving animals in the control groups became
FMD positive by 7 dpc and all animals in the FMD vaccinated
groups developed a substantial increase in FMDV-specific
neutralizing antibody response after challenge (Table 1, Fig. 5).
In both control groups viremia was detected at 1 dpc and
reached a peak of 1.5-3.5x106 pfu/ml at 2 dpc (Fig. 7A). In the
Fig.3. Expression of O1C capsid proteins in Ad5-O1C infected IB-RS-2
cells. [35S]methionine labeled lysates from Ad5-O1C infected IB-
RS-2 cells were immunoprecipitated with various antibodies and
proteins resolved by SDS-PAGE on a 15% gel. Lane 1: An FMDV
O1C infected IB-RS-2 cell lysate was immunoprecipitated with
convalescent serum from a bovine infected with FMDV. Lanes 2-6:
cell lysates from Ad5-O1C infected IB-RS-2 cells were immuno-
precipitated with convalescent serum from a bovine infected with
several serotypes (lane 2), normal bovine serum (lane 3),
convalescent serum from a bovine infected with FMDV O1C (lane
4), or polyclonal antibodies against FMDV A12 VP1 and VP2 (lanes
5 and 6, respectively).
Fig.4. BrdU proliferation assay. Recombinant pGM-CSF was added to
TF-1 cells and examined for incorporation of BrdU to generate a
standard curve. In the same assay supernatant fluids from Ad5-
pGMCSF and Ad5-Blue infected IB-RS-2 cells were titrated on TF-
1 cells and examined for cell proliferation. The units/ml of pGM-
CSF activity was determined from the standard curve (1 unit =
100 pg pGM-CSF).
Fig.5. Kinetics of induction of FMDV-specific neutralizing antibody
titers after Ad5 inoculation. Serum samples were obtained weekly
after Ad5 inoculation until 2 weeks postchallenge. The FMDV-
specific PRN70 titers were determined and expressed as the mean
of each group.
Fig.6. Appearance of clinical disease after FMDV challenge. Animals
were examined daily for vesicular lesions and the clinical score
was determined as described in the legend to Table 1. The mean
of each group is presented.
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FMD vaccinated groups, viremia was first detected in groups 4
and 5 (vaccine + pGMCSF) at 2-3 dpc and by 3-4 dpc in group 3
(vaccine alone). One pig in group 3 never developed viremia or
fever and a second animal only had a low level of viremia for 1
day (Fig. 7A).   Peak viremia was at 3 dpc in the dual-inoculated
groups and was approximately 1,000-fold lower as compared to
the controls (Fig. 7A). In the Ad5-O1C vaccinated animals, peak
viremia was at 4 dpc and was approximately 10,000-fold lower
than in the control pigs.
Virus present in nasal swabs reached a peak in both control
groups by 2-3 dpc and at 4 dpc in all three FMD vaccinated
groups (Fig. 7B). Group 3, vaccinated with only Ad5-O1C, had
the lowest levels of virus shedding.
DISCUSSION
We have previously demonstrated that a single IM inoculation of
Ad5-FMDV vectors containing the P1-2A coding regions from
A12 (Mayr et al. 2001) or A24 (Moraes et al. 2002) and the A12 3C
protease coding region can induce significant FMDV-specific
neutralizing antibody titers in swine and protect most or all of
the animals when challenged either by contact or direct
inoculation. However, inoculation with an Ad5 vector containing
the O1C capsid coding region or an Ad5 vector containing the
O1C capsid coding region in a bicistronic expression cassette
induces a significantly lower FMDV-specific neutralizing
antibody response in swine (unpublished observations; Wu et al.
2003b). Similar results have been reported with the conventional
inactivated FMD vaccine and therefore to be an efficacious
vaccine, manufacturers include a higher dose of type O 146S
antigen than type A in vaccine formulations (Pay & Hingley 1987,
Doel et al. 1994).
To enhance the immune response induced by Ad5-O1C, we
tested a vaccination regimen that included co-administration of
pGM-CSF, a cytokine that has been shown to enhance the immune
response of animals to some vaccines (Xiang & Ertl 1995, Lee et
al. 1998, Somasudaran et al. 1999, Cedillo-Barrón et al. 2001,
Barouch et al. 2002).  We constructed an Ad5-pGMCSF virus that
expressed biologically active pGM-CSF. Swine inoculated with
Ad5-O1C and either a low or high dose of Ad5-pGMCSF developed
a detectable FMDV-specific neutralizing antibody response pri-
or to the animals administered only Ad5-O1C, ie., by 4 days, and
the response was higher at 1 week postinoculation. However, by
2 weeks postinoculation and at the time of challenge the
neutralizing antibody response of these 3 groups was equivalent
(Fig. 5) and was considerably lower than the response to one
inoculation of Ad5-A12 or Ad5-A24 (Mayr et al. 2001, Moraes et
al. 2002). Thus, the co-administration of Ad5-pGMCSF did not
enhance the long-term FMDV-specific neutralizing antibody
response.
After challenge the control groups (Groups 1 and 2) rapidly
developed significant disease and all 3 animals in Group 1
and one of 3 animals in Group 2 died. The histopathology
findings upon necropsy of the four animals that died after
challenge revealed that they all had severe vesicular lesions
on the mouth and all feet, resembling typical FMD lesions,
and moderate to severe myocardial necrosis resulting in heart
failure, which was most likely the result of FMDV infection. In
previous experiments with FMDV serotype A, control groups
of swine rapidly developed significant disease after direct
inoculation challenge, but did not die if they were healthy
prior to the start of the experiment (Moraes et al. 2002,
Chinsangaram et al. 2003, Moraes et al. 2003), suggesting
that the challenge virus used in the present studies was either
too virulent or the dose used was excessive. In subsequent
titration of this virus, 1/100th the dose used in this study still
resulted in the death of 1 of 2 naïve animals and the animal
that survived had severe disease including loss of hoofs. In
either case the “over-challenge”, in this experiment, masked
the protective effects of the Ad5-O1C vaccine, since all
vaccinated animals developed vesicular lesions and 3 of 4
animals had viremia. However, vaccination with Ad5-O1C
clearly delayed and reduced the severity of disease. None of
the animals inoculated with only Ad5-O1C died or lost their
hoofs, the appearance of vesicular lesions was delayed for 1-
B
A
Fig.7. Virus present in blood and nasal secretions after challenge.
Panel A: Viremia in Ad5 inoculated pigs after FMDV challenge.
Blood samples were obtained daily for 7 days postchallenge and
virus titers, pfu/ml, determined by plaque assay on BHK-21 cells.
The mean of each group is displayed. Panel B: Virus in nasal
swabs of Ad5 inoculated pigs after FMDV challenge. Nasal swabs
were obtained daily for 6 days postchallenge and virus titers, pfu/
ml, determined by plaque assay on BHK-21 cells. The mean of
each group is displayed.
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2 days as compared to the control groups and was less severe.
Furthermore, the peak of viremia was delayed 2 days, one
animal never developed viremia, and virus titers were
approximately 10,000-fold lower than in the controls, and
the peak of virus shedding was delayed 2 days.
The addition of pGM-CSF did not enhance the efficacy of the
Ad5-O1C vaccine. Although none of the animals given Ad5-
pGMCSF died or lost their hoofs, all developed vesicular lesions
that were somewhat more severe than the Ad5-O1C vaccinated
animals. Furthermore, while viremia was delayed and reduced
as compared to the control groups all of these effects can be
attributed to the vaccine alone, as the Ad5-O1C inoculated animals
had even lower levels of viremia.
We have subsequently repeated this experiment, and included
a second route of inoculation, and obtained very similar results.
Swine inoculated with Ad5-O1C IM with a needle or
subcutaneously/IM by needleless delivery and challenged had
no detectable viremia and clinical disease was delayed and less
severe than control animals (data not shown). However, the
addition of Ad5-pGMCSF reduced the level of protection afforded
by the vaccine alone.
Cedillo-Barrón et al. (2001) demonstrated that the addition
of plasmid encoded pGM-CSF along with a DNA based FMDV
empty capsid vaccine resulted in a statistically significant increase
in the antibody levels against FMDV and somewhat improved the
protection of vaccinated swine as compared to swine only given
the empty capsid vaccine. However, in these studies the swine
were challenged after 3 DNA inoculations and the increase in
FMDV-specific antibody levels was only detected after the second
inoculation. Additional studies examining the adjuvant effect of
GM-CSF for other antigens have suggested that the presence of
this cytokine at the site of vaccine inoculation is important (Wang
et al. 2002) and that plasmids co-expressing antigen and GM-CSF
are more effective than co-administration of plasmids separately
expressing each antigen (Lee et al. 1998, Barouch et al. 2002,
Sun et al. 2002).
While our results do not agree with the findings of Cedillo-
Barrón et al. (2001), it may be that factors including the level of
expression of both the immunogen and the adjuvant, the type of
cells expressing these proteins, as well as the proximity of antigen
and adjuvant expression in the animal can have profound effects
on induction of protective responses. Experiments to examine
these factors as well as a more basic understanding of the host
cell response to FMDV infection may help us identify cytokines
that can potentially enhance the immune response to FMD vaccine
candidates.
CONCLUSION
In previous work, we have demonstrated that swine given one
dose of an Ad5-O1C vector developed only low FMDV-specific
neutralizing antibody titers. To attempt to enhance the potency
and efficacy of this vaccine, groups of swine were given either
one inoculation of an Ad5-O1C vector or a combination of Ad5-
O1C and an Ad5 vector containing the cytokine pGM-CSF at two
different doses. Animals were challenged 3 weeks later by direct
inoculation with virulent FMDV. Although the swine inoculated
with only Ad5-O1C did not develop a significant FMDV-specific
neutralizing antibody response and did develop clinical disease
after challenge, disease signs and viremia were considerably
reduced as compared to control groups. While the addition of
Ad5-pGMCSF induced a more rapid neutralizing antibody
response, it adversely affected the level of protection afforded
by the Ad5-O1C vaccine alone.
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